Chronic obstructive pulmonary disease (COPD) is one of the most common pathologies of the respiratory system and is often the cause of disability and mortality of this category of patients. An unfavorable prognosis is often due to late diagnosis of COPD. Over the past decade, certain successes have been achieved in the study of pathogenesis, clinic, early diagnosis and treatment of COPD. COPD therapy includes pharmacological and non-pharmacological approaches that can significantly reduce clinical symptoms and reduce the frequency of exacerbations of the disease.  Mucolytic  therapy such as N-acetylcysteine, ambroxol, or carbocysteine may also be considered in patients with chronic bronchitis. Our study showed that when N-acetylcysteine was included in the complex treatment of moderate COPD in the acute stage, SpO2 levels significantly increased, shortness of breath, cough symptoms and the amount of sputum excreted decreased, which significantly improves the clinical picture and quality of life of patients.

chronic obstructive pulmonary disease, treatment, mucolytic therapy, N-acetylcysteine

Liverko I.V. et al. Epidemiological situation of chronic obstructive pulmonary disease in the world and in Uzbekistan / I. V. Liverko, Yu. E. Fattakhova, R. A. Nalibayeva. A young scientist. 2021;40(382):47-51. URL: https://moluch.ru/archive/382/84336/.

Ovcharenko S.I., Kapustina V.A. The role of N-acetylcysteine in the complex treatment of patients with chronic obstructive pulmonary disease. Clinician.2010;1:64-68.

Chuchalin A.G. et al. Chronic obstructive pulmonary disease: federal clinical guidelines for diagnosis and treatment/ Chuchalin A.G., Avdeev S.N., Aisanov Z.R., Belevsky A.S., Leshchenko I.V., Ovcharenko S.I., Shmelev E.I. Pulmonology. 2022;32(3):356-392. https://doi.org/10.18093/0869-0189-2022-32-3-356-392.

Yamashkina A.S. Chronic obstructive pulmonary disease. student. 2020;No.11. URL: https://cyberleninka.ru/article/n/hronicheskaya-obstruktivnaya-bolezn-legkih-3.

Kazzola M., Calcita L., Page S. et al. The effect of N-aetilhisteine on genetic bronchitis or other activity: meta-analysis. Euro. Respir. Editorial 2015; 24 (137): 451-461. DOI: 10.1183/16000617.00002215.

Matsunaga K., Oishi K., Miravitles M., Anzueto A. It's Time To Revise The Algorithm Of COLD Treatment. June 2019, 14:2229-2234.

Pool P., Black P.N., Kats K.J. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. The Cochrane database system. Revision 2012; (8): CD001287. DOI: 10.1002/14651858.CD001287. pub4.